Researchers have engineered a drug treatment that shows rapid effectiveness against endometriosis in early testing, laying the foundation for a potential therapy for an incurable, chronic disease that affects 1 in 10 women. The targeted nanotherapy, developed by a team of scientists at Washington State University, reduced endometriosis symptoms and disease progression after a single dose in a mouse model.

The treatment targets a cell associated with endometriosis with a commonly available drug delivered by a tiny nanoparticle. The results were published in the journal Advanced Healthcare Materials, and the researchers hope to eventually test the drug for human use.

“We found the disease-specific immune cell, and then we had a drug, but we couldn’t target the cell with the drug alone,” said Kanako Hayashi, a professor in WSU’s School of Molecular Biosciences in the College of Veterinary Medicine and a corresponding author of the new publication. “So we used this nanocarrier that delivers the drug specifically to the disease site.”